Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study
Highlight
– Oral metformin treatment in patients with low-grade non-muscle-invasive bladder cancer showed limited antitumor efficacy, with only one complete and one partial response among 11 patients.
– Metformin was well-tolerated, with mild diarrhea being the most common adverse event.
– Urinary metformin concentrations exceeded systemic blood levels, but no significant changes were observed in immunohistochemical markers linked to metformin’s proposed mechanisms of action.
– The study concludes that oral metformin lacks conclusive evidence for antitumor benefit in NMIBC marker lesions.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.